INTEGRA LIFESCIENCES HOLDINGS CORP 10-Q

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Recent Sale of Unregistered Securities: None. Purchases of Equity Securities: 46 Table of Contents The following table provides information about purchases by the Company during the quarter ended June 30, 2024 of equity securities that are registered by us pursuant to Section 12 of the Exchange Act. Subject to applicable law, share repurchases may be made from time to time in open market transactions, privately negotiated transactions including accelerated share repurchase agreements, or pursuant to instruments and plans complying with Rule 10b5-1 under the Exchange Act, among other types of transactions and arrangements. Issuer purchases of equity securities Period Total number of shares purchased Average price paid per share Total number of shares purchased as part of publicly announced repurchase programs Approximate dollar value of shares that may yet be purchased under the plans or program 04/01/2024 - 04/30/2024 05/01/2024 - 05/31/2024 1,273,190 $ 39.27 1,273,190 50,000,000 06/01/2024 - 06/30/2024 1,273,190 1,273,190 On May 16, 2024, the Company entered into a $50 million accelerated share repurchase (“May 2024 ASR”) and received 1.3 million shares of common stock at inception of the May 2024 ASR, which represented approximately 70% of the expected total shares under the May 2024 ASR. The remaining repurchase transactions are expected to be completed in the third quarter of 2024. According to the terms of our Senior Credit Facility, our ability to declare or make any dividend payments is limited. See Note 6. Debt , to the Notes to Unaudited Condensed Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for a description of working capital restrictions and limitation on the payment of dividends. ITEM 3. DEFAULTS UPON SENIOR SECURITIES Not applicable. ITEM 4. MINE SAFETY DISCLOSURES Not applicable.